A New Generation of DDR Targeting Drugs: DNA Decoy Agonists of DNAPK & PARP1

Time: 5:00 pm
day: Day One


  • The DDR pathway is made up of well-orchestrated machinery, with redundant pathways that could take over when one enzyme/pathway is inhibited commonly leading to acquired resistance to small molecules inhibitors
  • Onxeo developed a cutting-edge new technology to trap DDR proteins and abrogate the DNA repair machinery to trap and hyperactivate DDR enzymes, inducing a false damage signaling in tumor cells
  • These Decoy Agonists are under clinical or preclinical investigations